Announcement of The Consolidated Financial Report for The 2nd Quarter of 2024
2024.8.8
Provided by: TTY BIOPHARM COMPANY LIMITED
| SEQ_NO | 1 | Date of announcement | 2024/08/08 | Time of announcement | 17:55:26 |
| Subject | Announcement of The Consolidated Financial Report for The 2nd Quarter of 2024 | ||||
| Date of events | 2024/08/08 | To which item it meets | paragraph 31 | ||
| Statement | 1.Date of the board of directors submitted or approved:2024/08/08 2.Date of the audit committee approved:2024/08/08 3.Start and end dates of financial reports or unaudited financial information of the reporting period:2024/01/01~2024/06/30 4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):2,648,256 5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):1,580,639 6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):592,792 7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):717,570 8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):566,703 9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):542,482 10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):2.18 11.Total assets end of the period (thousand NTD):10,249,880 12.Total liabilities end of the period (thousand NTD):3,740,352 13.Equity attributable to owners of parent end of the period (thousand NTD):5,806,211 14.Any other matters that need to be specified:None. |
||||